News & Analysis on Clinical Trial Services & Contract Research And Development
German chemical company Bayer has posted flat first-quarter 2004 sales, but said that the results were on track given the negative effects of currency factors. Organic sales growth rose 8.6 per cent, it claimed, and was driven mainly be the healthcare...
France's Stedim and Integrated Biosystems have been awarded two new patents on their Celsius line of containers, currently being launched in Europe and US, that are used in the production of biopharmaceuticals.
Researchers in Belgium have developed a new generation of drugs consisting of extremely small antibodies - called nanobodies - that can target tumour cells specifically and seem suitable for oral delivery.
Germany's atugen, a specialist in RNA interference technologies for switching off genes, has demonstrated the feasiblity of delivering a small interfering RNA (siRNA)-based drug and achieving a physiological response in animals.
Avecia Pharmaceuticals has consolidated its position in the evolving Japanese pharmaceutical market by forging a technology agreement with a local company,reports Phil Taylor.
Germany's Evotec recording a loss in the first quarter of 2004 due in part, to what it said was a difficult operating environment for companies supplying drug discovery technologies.
A US inventor claims to have developed a process that would enable tablets to be made in three simple steps, eliminating the need for preprocessing.
Switzerland's Metrohm has developed a new delivery system for reagents used in ion chromatography that is designed to reduce wastage, improve safety in the lab and does away with the need to dispose of spent eluent cartridges.